Document:USA FDA - E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1): Guidance for Industry March 2018: Difference between revisions
From GxPlex
gxplex>GxPlexBot Import from GxPlex Excel |
Remove static References table, superseded by live #ask in Template:DocumentData (GxPlexBot) |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{DocumentData | |||
|reference=USA FDA - E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1): | |reference=USA FDA - E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1): | ||
Guidance for Industry March 2018 | Guidance for Industry March 2018 | ||
| Line 37: | Line 18: | ||
|contributors= | |contributors= | ||
}} | }} | ||
Latest revision as of 14:15, 16 July 2026
| Document information | |
|---|---|
| Reference | USA FDA - E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1):
Guidance for Industry March 2018 |
| Validity area | USA |
| Scope(s) | G |
| Document name | FDA - E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1):
Guidance for Industry |
| Version / Revision | March 2018 |
| Status | Current |
| Document type | Official recommendation |
| Language(s) | EN |
| Description | GUIDANCE DOCUMENT
E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
References
| Scope | Document part | Language | Preview | |
|---|---|---|---|---|
| USA FDA - E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1): Guidance for Industry March 2018 - | G | - | EN | This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for … |